1. Home
  2. BTCT vs GNPX Comparison

BTCT vs GNPX Comparison

Compare BTCT & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTCT

BTC Digital Ltd.

HOLD

Current Price

$1.20

Market Cap

12.7M

Sector

Real Estate

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$0.86

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTCT
GNPX
Founded
2006
2009
Country
Singapore
United States
Employees
21
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.7M
11.8M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
BTCT
GNPX
Price
$1.20
$0.86
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
71.5K
732.3K
Earning Date
05-29-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$283.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$0.14
52 Week High
$4.72
$12.97

Technical Indicators

Market Signals
Indicator
BTCT
GNPX
Relative Strength Index (RSI) 46.15 20.65
Support Level $1.09 $0.15
Resistance Level $1.23 $2.12
Average True Range (ATR) 0.09 0.11
MACD 0.00 -0.01
Stochastic Oscillator 34.48 1.25

Price Performance

Historical Comparison
BTCT
GNPX

About BTCT BTC Digital Ltd.

BTC Digital Ltd is a crypto asset technology company based in the U.S. with a focus on bitcoin mining. The company also generates revenue through mining machine resale and rental business operations. Geographically, the financial assets of the company is located in the United States, Singapore, Hong Kong and the PRC.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

Share on Social Networks: